As a potent inhibitor for multiple DTC receptor tyrosine kinases, Cabozantinib can inhibit MET, RET, and VEGFR phosphorylation as well as VEGF-induced tumor cell invasion, metastasis, and endothelial cell tube formation [155,156]. This evidence concerns the gene VEGFA and neoplasm.